XOMA GAAP EPS of $0.44 beats by $0.59, revenue of $13.13M beats by $3.74M

* XOMA press release [https://seekingalpha.com/pr/20199201-xoma-royalty-reports-second-quarter-and-year-to-date-2025-financial-results-and-highlights] (NASDAQ:XOMA [https://seekingalpha.com/symbol/XOMA]): Q2 GAAP EPS of $0.44 beats by $0.59.
* Revenue of $13.13M (+18.3% Y/Y) beats by $3.74M.

MORE ON XOMA

* I'm Staying Neutral On XOMA Royalty After The LAVA And HilleVax Deals [https://seekingalpha.com/article/4809382-xoma-royalty-i-staying-neutral-stock-after-lava-hillevax-deals]
* XOMA Royalty to acquire cancer drug developer LAVA Therapeutics [https://seekingalpha.com/news/4477180-lava-therapeutics-stock-gains-ma-deal-with-xoma]
* Turnstone Biologics to be acquired by XOMA Royalty [https://seekingalpha.com/news/4463228-turnstone-biologics-acquired-xoma-royalty]
* Seeking Alpha’s Quant Rating on XOMA [https://seekingalpha.com/symbol/XOMA/ratings/quant-ratings]
* Historical earnings data for XOMA [https://seekingalpha.com/symbol/XOMA/earnings]